Low-dose cyclophosphamide-induced hyponatremia in primary breast cancer

Abstract

Hyponatremia is the most common electrolyte disturbance seen in patients receiving anticancer drugs. Several cytotoxic agents, including carboplatin, cisplatin, vincristine, and vinblastine, have been found to cause hyponatremia. Recently, clinically significant hyponatremia has been reported in cancer patients treated with moleculartargeted therapies [1]. Moreover, several studies have suggested that hyponatremia is a poor prognostic factor among cancer patients [2,3].